Streetwise Reports' Article Archives — December 2018 back to current month (14)
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm.
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH.
A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza.
A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study.
Urgent Update on Canadian Health Company Acquisition (12/18/2018)
Technical analyst Clive Maund charts the potentially transformative acquisition of a medical software provider in Canada.
With the U.S. government legalizing hemp in the recently passed 2018 Farm Bill, Fincom Investment Partners profiles a hemp company whose largest market is the U.S.
Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada.
A William Blair report reviewed the firm's operational and financial numbers for the period.
Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition.
Strong Health Stock 'Ready to Commence New Upleg' (12/11/2018)
Technical analyst Clive Maund analyzes a rapidly expanding company with medical clinics in British Columbia that is using advanced technology and AI.
Technical analyst Clive Maund charts a telemedicine technology company and explains why he believes the company's stock should rebound.
A company in Canada that is changing the paradigm for providing healthcare in Canada and potentially elsewhere by integrating technology and artificial intelligence has just announced a major acquisition.
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application.
This company takes a step forward in its efforts to protect its intellectual property.
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|